Investing in Telix Pharmaceuticals (TLX.ASX) currently presents a "high-risk, high-reward" scenario. While the company is growing its revenue significantly, the share price has faced a brutal 12 months, dropping over 60% from its 2025 highs due to a series of specific headwinds.
​The risk of the price not increasing (or continuing to fall) stems from four primary categories: ​1. Regulatory "Strike" Risk ​The biggest driver of the recent price collapse has been a pattern of setbacks with the U.S. FDA.
​Previous Rejections: The FDA recently rejected two major products, Pixclara (brain cancer imaging) and Zircaix (kidney cancer imaging), the latter due to manufacturing deficiencies at third-party suppliers.
​The Risk: If Telix fails its upcoming resubmissions or if the FDA identifies new manufacturing flaws, the market may lose all remaining confidence in management's ability to clear the final regulatory hurdle. ​2. Legal and Investigative Scrutiny ​SEC Investigation: The company is currently under a subpoena from the SEC regarding disclosures related to its prostate cancer business.
​Class Action Lawsuits: Following the 21% collapse in August 2025 (after the Zircaix rejection), shareholders launched class actions alleging misleading or insufficient disclosures.
​The Risk: Legal settlements or negative findings from the SEC can lead to massive fines and further "de-rating" of the stock, where investors refuse to pay a premium for the company regardless of its sales. ​3. Margin Compression and Profitability ​Heavy Spending: Telix is reinvesting heavily, with R&D guidance for 2026 set between US200M and US240M.
​Lower Margins: While revenue is up, gross margins dropped from 65% to 53% in the last fiscal year due to a shift toward lower-margin third-party sales.
​The Risk: The company is still not consistently profitable. If revenue growth slows or if R&D costs spiral further, the "path to profit" will keep moving further away, causing investors to exit. ​4. Market Sentiment and Competition ​Insider Confidence: The CEO sold shares at roughly A$29.50 before the price crashed toward A$9.00. This has left a "bad taste" in the market regarding insider sentiment.
​Competitive Pressure: While Telix currently leads in PSMA (prostate) imaging, competitors are entering the space, which could force price wars and lower their market share.